Inventiva vs Taysha Gene Therapies
Taysha Gene Therapies is the larger business, with $9.8m of revenue in fiscal 2025 against $5.1m for Inventiva (1.9 times as much). Taysha Gene Therapies grew faster (17.3% against -49.1%). Taysha Gene Therapies kept more of each dollar of sales as profit: a net margin of -1115.3% against -7899.6%.
| Latest fiscal year | InventivaIVA, 2025 | Taysha Gene TherapiesTSHA, 2025 |
|---|---|---|
| Revenue | $5.1m | $9.8m |
| Revenue growth | -49.1% | 17.3% |
| Net income | −$400m | −$109m |
| Operating margin | -3145.5% | -1130.6% |
| Net margin | -7899.6% | -1115.3% |
| Return on equity | — | -68.5% |
| Free cash flow | — | −$93.8m |
| Cash | $117m | $320m |
| Total debt | $70.3m | $50.1m |
| Debt to equity | — | 20.3% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | — | 99 |
| Market value | $795m | $1.32bn |
| Price vs our value range | — | — |
| Moat score | — | — |
| Insider trades, 12 months | 0 buys, 0 sales | 0 buys, 12 sales |